[HTML][HTML] Cancer bioenergetics and tumor microenvironments—Enhancing chemotherapeutics and targeting resistant niches through nanosystems
Simple Summary Cancer remains a major killer of the human population. Current cancer
diagnostic and therapeutic methods are associated with shortcomings of limited targetability …
diagnostic and therapeutic methods are associated with shortcomings of limited targetability …
[HTML][HTML] Genomic and transcriptomic research in the discovery and application of colorectal cancer circulating markers
AA Ponomaryova, EY Rykova, AI Solovyova… - International Journal of …, 2023 - mdpi.com
Colorectal cancer (CRC) is the most frequently occurring malignancy in the world. However,
the mortality from CRC can be reduced through early diagnostics, selection of the most …
the mortality from CRC can be reduced through early diagnostics, selection of the most …
[HTML][HTML] Leptomeningeal metastases in melanoma patients: an update on and future perspectives for diagnosis and treatment
J Steininger, FF Gellrich, K Engellandt… - International journal of …, 2023 - mdpi.com
Leptomeningeal disease (LMD) is a devastating complication of cancer with a particularly
poor prognosis. Among solid tumours, malignant melanoma (MM) has one of the highest …
poor prognosis. Among solid tumours, malignant melanoma (MM) has one of the highest …
Performance evaluation of a CRISPR Cas9-based selective exponential amplification assay for the detection of KRAS mutations in plasma of patients with advanced …
Y Shen, X Zhang, L Zhang, Z Zhang, B Lyu… - Journal of Clinical …, 2023 - jcp.bmj.com
Aims Pancreatic ductal adenocarcinoma (PDAC) is highly malignant, with shockingly
mortality rates. KRAS oncoprotein is the main molecular target for PDAC. Liquid biopsies …
mortality rates. KRAS oncoprotein is the main molecular target for PDAC. Liquid biopsies …
[HTML][HTML] Early prognosis prediction in acute myeloid and acute lymphoid leukemia patients using cell-free DNA concentration ratios
Background: Cell-free DNA (cfDNA) is a promising biomarker for disease prediction in many
cancers, including acute leukemia (acute myeloid leukemia [AML] and acute lymphoblastic …
cancers, including acute leukemia (acute myeloid leukemia [AML] and acute lymphoblastic …
[HTML][HTML] Blood Plasma Circulating DNA-Protein Complexes: Involvement in Carcinogenesis and Prospects for Liquid Biopsy of Breast Cancer
A Shefer, O Tutanov, M Belenikin… - Journal of Personalized …, 2023 - mdpi.com
Circulating DNA (cirDNA) is a promising tool in translational medicine. However, studies of
cirDNA have neglected its association with proteins, despite ample evidence that this …
cirDNA have neglected its association with proteins, despite ample evidence that this …
Measuring cfDNA integrity as a biomarker for predicting neoadjuvant chemotherapy response in breast cancer patients: a pilot study
C Giro, AMTD Yamada, FJSM Cruz… - Breast Cancer Research …, 2024 - Springer
Purpose Circulating cell-free DNA (cfDNA) is a promising biomarker for predicting treatment
response and disease outcomes in Breast Cancer (BC) patients undergoing neoadjuvant …
response and disease outcomes in Breast Cancer (BC) patients undergoing neoadjuvant …
[HTML][HTML] Clinical Implication of Concurrent Amplification of MET and FGFR2 in Metastatic Gastric Cancer
S Byeon, J Jung, ST Kim, KM Kim, J Lee - Biomedicines, 2023 - mdpi.com
Background: c-mesenchymal epithelial transition factor receptor (c-MET) and fibroblast
growth factor receptor 2 (FGFR2) amplification have been identified as factors associated …
growth factor receptor 2 (FGFR2) amplification have been identified as factors associated …
[HTML][HTML] Next-Generation Sequencing-Based Molecular Profiling Using Cell-Free DNA: A Valuable Tool for the Diagnostic and Prognostic Evaluation of Patients With …
MA Jang - Annals of Laboratory Medicine, 2024 - ncbi.nlm.nih.gov
NGS-based cfDNA analysis using the Oncomine Pan-Cancer Cell-Free Assay (Thermo
Fisher Scientific, Waltham, MA, USA) and AlphaLiquid 100 kit (IMBdx, Seoul, Korea). In this …
Fisher Scientific, Waltham, MA, USA) and AlphaLiquid 100 kit (IMBdx, Seoul, Korea). In this …
Exploring the Role of Circulating Cell-Free DNA in Disease Diagnosis and Therapy
M Odah - 2024 - preprints.org
Recent advancements in molecular diagnostics have highlighted the potential of circulating
cell-free DNA (ccfDNA) as a biomarker in various diseases. This study aims to explore the …
cell-free DNA (ccfDNA) as a biomarker in various diseases. This study aims to explore the …